Stock DNA
Pharmaceuticals & Biotechnology
PKR 53,390 Million (Large Cap)
15.00
NA
1.10%
0.69
29.80%
3.75
Revenue and Profits:
Net Sales:
7,160 Million
(Quarterly Results - Mar 2025)
Net Profit:
1,057 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.51%
0%
-1.51%
6 Months
11.01%
0%
11.01%
1 Year
125.12%
0%
125.12%
2 Years
257.37%
0%
257.37%
3 Years
119.68%
0%
119.68%
4 Years
82.7%
0%
82.7%
5 Years
61.79%
0%
61.79%
AGP Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
32.92%
EBIT Growth (5y)
30.22%
EBIT to Interest (avg)
7.47
Debt to EBITDA (avg)
1.07
Net Debt to Equity (avg)
0.67
Sales to Capital Employed (avg)
0.95
Tax Ratio
34.87%
Dividend Payout Ratio
41.95%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
24.53%
ROE (avg)
18.74%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
4.07
EV to EBIT
8.25
EV to EBITDA
7.86
EV to Capital Employed
2.77
EV to Sales
2.53
PEG Ratio
0.16
Dividend Yield
1.05%
ROCE (Latest)
33.63%
ROE (Latest)
27.59%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY
Mar'25
Mar'24
Change(%)
Net Sales
7,159.60
5,920.40
20.93%
Operating Profit (PBDIT) excl Other Income
2,285.10
1,539.80
48.40%
Interest
385.30
730.00
-47.22%
Exceptional Items
0.00
0.00
Consolidate Net Profit
1,056.80
467.10
126.25%
Operating Profit Margin (Excl OI)
304.80%
245.50%
5.93%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2025 is 20.93% vs 51.86% in Mar 2024
Consolidated Net Profit
YoY Growth in quarter ended Mar 2025 is 126.25% vs 18.07% in Mar 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
25,033.60
18,743.10
33.56%
Operating Profit (PBDIT) excl Other Income
7,305.90
4,652.60
57.03%
Interest
2,693.10
1,629.10
65.31%
Exceptional Items
0.00
0.00
Consolidate Net Profit
2,960.60
1,823.10
62.39%
Operating Profit Margin (Excl OI)
291.80%
231.20%
6.06%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 33.56% vs 29.63% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 62.39% vs 6.94% in Dec 2023
About AGP Ltd. 
AGP Ltd.
Pharmaceuticals & Biotechnology
AGP Limited is a Pakistan-based pharmaceutical company that manufactures, markets and distributes pharmaceutical and healthcare products. The Company provides products in the areas of anti-infective, antihistamines, antidepressants, anti fibrinolytic, antiobesity, bile therapy and cholagogue, iron preparation, narcotic analgesic, proton pump inhibitor, vitamin B12, anti-inflammatory enzyme, anti-diarrheal, antidiabetic, anti haemorrhoidal, antispasmodics, calcium preparation, medical food supplement, non-narcotic analgesic, tonic, vitamin D plain, anti allergics, antibiotics, antidiarrheal supplement, antimalarial, antiviral, expectorant, muscle relaxant and venotropic agent. The Company sells products under various brands, including Ceclor, Rigix, Osnate, Anafortan, MyHep, Keflex, Chymoral Forte, Splasler P, Urso and Rubifer.
Company Coordinates 
Company Details
B-23, S.I.T.E , Karachi None : 75700
Registrar Details






